These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 32452543)
41. Development and validation of a multivariable prediction rule for detecting a severe acquired ADAMTS13 activity deficiency in patients with thrombotic microangiopathies. Nieto JM; De La Fuente-Gonzalo F; González FA; Villegas A; Martínez R; Fuentes ME; Ropero P Clin Chem Lab Med; 2018 Jan; 56(2):294-302. PubMed ID: 28796639 [TBL] [Abstract][Full Text] [Related]
43. [ADAMTS13 and thrombotic thrombocytopenic purpura retrospective study at the hospital of Le Mans]. Bovet J; Pineau-Vincent F Ann Biol Clin (Paris); 2014; 72(3):321-30. PubMed ID: 24876143 [TBL] [Abstract][Full Text] [Related]
44. Validation of the PLASMIC score, a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis, in Chinese patients. Tang N; Wang X; Li D; Sun Z Thromb Res; 2018 Dec; 172():9-13. PubMed ID: 30340093 [TBL] [Abstract][Full Text] [Related]
45. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285 [TBL] [Abstract][Full Text] [Related]
46. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment. le Besnerais M; Veyradier A; Benhamou Y; Coppo P Expert Opin Biol Ther; 2019 Nov; 19(11):1127-1134. PubMed ID: 31359806 [No Abstract] [Full Text] [Related]
48. A case of severe ADAMTS13 deficiency presenting as thrombotic thrombocytopenic purpura in pregnancy. Nikolaou M; Karakantza M; Adonakis G; Theodorou G; Zoumbos N; Decavalas G Med Pregl; 2012; 65(9-10):436-9. PubMed ID: 23214340 [TBL] [Abstract][Full Text] [Related]
55. Predicting 5-Year Risk of RRT in Stage 3 or 4 CKD: Development and External Validation. Schroeder EB; Yang X; Thorp ML; Arnold BM; Tabano DC; Petrik AF; Smith DH; Platt RW; Johnson ES Clin J Am Soc Nephrol; 2017 Jan; 12(1):87-94. PubMed ID: 28028051 [TBL] [Abstract][Full Text] [Related]